Mode
Text Size
Log in / Sign up

PET-guided radiation dose escalation linked to improved event-free survival in prostate cancer recurrenceCan more targeted radiation help men whose prostate cancer returns after surgery?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider PET-guided RT dose escalation for prostate cancer recurrence, but note comparison is to historical control.

The EMPIRE-2 trial was a randomized study of 140 men with biochemical progression of prostate cancer after prostatectomy and negative conventional imaging findings. Patients received radiation therapy dose escalation (≥76.0 Gy to prostate bed and ≥56.0 Gy to pelvis) guided by either [F]-fluciclovine PET (59 completed RT) or [Ga]-PSMA-11 PET (60 completed RT), with median follow-up of 2.6 years.

Compared to the [F]-fluciclovine RT arm from the prior EMPIRE-1 trial (without dose escalation), the overall EMPIRE-2 cohort showed improved 2-year event-free survival (87% vs. 80%, difference 7.7%, 95% CI 4.7-12%, p=0.01). After propensity score weighting, the difference was 84% vs. 73% (difference 11%, 95% CI 3.6-24%, p=0.01). Within EMPIRE-2, there was no significant difference between the two PET tracers (87% vs. 88%, difference 0.7%, 95% CI 0.3-1.3%, p>0.9).

Safety and tolerability data were not reported. Key limitations include the comparison to a historical cohort rather than a concurrent control group, and the relatively short median follow-up of 2.6 years. The study did not report adverse events, serious adverse events, or discontinuation rates.

For practice, these results suggest that using either [F]-fluciclovine or [Ga]-PSMA-11 PET to guide radiation dose escalation to sites of PET uptake may be associated with improved event-free survival compared to approaches without dose escalation. However, the evidence comes from comparison to a historical control, and longer-term outcomes and safety data are needed before definitive conclusions can be drawn.

When prostate cancer returns after surgery, it can be a frightening setback. A new study looked at whether using advanced PET scans to guide more powerful, targeted radiation could help men in this situation. The scans help doctors see exactly where the cancer cells are hiding, so they can aim a stronger dose of radiation right at those spots.

The trial involved 140 men whose cancer had returned but didn't show up on standard scans. They were randomly assigned to have their radiation guided by one of two types of PET scans. After about two and a half years, 87% of men who got this more targeted, higher-dose treatment were still event-free, compared to 80% of men in a previous trial who got a different treatment. When researchers adjusted the numbers to better compare the groups, the difference was even larger.

It's important to note that the two different PET scans used in the new trial worked equally well. The main finding is that this approach of using a scan to guide a stronger radiation dose was linked to better outcomes. However, the comparison group came from an older trial, not from a group treated at the same time. The median follow-up was just 2.6 years, so we don't yet know the long-term effects. The study didn't report on side effects or how well men tolerated the stronger radiation.

What this means for you:
More precise, higher-dose radiation guided by PET scans was linked to better short-term outcomes for recurrent prostate cancer.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND AND OBJECTIVE: In EMPIRE-1, [F]-fluciclovine positron emission tomography (PET) imaging to guide salvage radiotherapy (RT) for prostate cancer recurrence after prostatectomy resulted in an improvement in event-free survival (EFS) over conventional imaging alone. The aim of EMPIRE-2 was to explore the impact of RT dose escalation to sites of uptake on PET in comparison to EMPIRE-1. METHODS: EMPIRE-2 was a randomized trial of [F]-fluciclovine versus [Ga]-PSMA-11 in a cohort of men with biochemical progression after prostatectomy and negative conventional imaging findings. After stratification, patients were randomized to RT guided by [F]-fluciclovine PET (arm 1) or [Ga]-PSMA-11 PET (arm 2). PET findings were used for treatment decisions and for RT dose escalation (≤76.0 Gy to the prostate bed and ≤56.0 Gy to the pelvis). The primary endpoint was 2-yr EFS in comparison to the [F]-fluciclovine RT arm in EMPIRE-1. The secondary endpoint was a planned EFS comparison for [F]-fluciclovine versus [Ga]-PSMA-11 in EMPIRE-2. KEY FINDINGS AND LIMITATIONS: In the cohort of 140 patients, 59 randomized to arm 1 patients and 60 randomized to arm 2 completed RT. Median follow-up was 2.6 yr (interquartile range 1.8-4.0). The 2-yr EFS rates were 87% for the overall EMPIRE-2 cohort versus 80% for the EMPIRE-1 comparison cohort (difference 7.7%, 95% confidence interval [CI] 4.7-12%; p = 0.01). After propensity score weighting, the corresponding 2-yr EFS rates were 84% versus 73% (difference 11%, 95% CI 3.6-24%; p = 0.01). The 2-yr EFS rates in the EMPIRE-2 study arms were 87% for [F]-fluciclovine versus 88% for [Ga]-PSMA-11 (difference 0.7%, 95% CI 0.3-1.3%; p > 0.9). CONCLUSIONS AND CLINICAL IMPLICATIONS: Use of either [F]-fluciclovine or [Ga]-PSMA-11 imaging to guide RT dose escalation to sites of PET uptake in the prostate bed and/or pelvis was associated with an improvement in EFS in comparison to a prior trial without dose escalation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.